Skip to content
How It Works
Explore
Resources Ask a Question
Who It's For
Patients
Decode results, prep for appointments, weigh options.
Caregivers & advocates
Carry the research load for someone you love.
Providers & clinicians
Resources for patients in your practice.
Log In Ask a Question
PubMed This is a summary of 16 peer-reviewed journal articles Updated
Hematology

Introduction and Orientation to Systemic Mastocytosis

At a Glance

Systemic mastocytosis (SM) is a rare blood disorder where the body produces too many mast cells, primarily driven by the KIT D816V mutation. Most cases are indolent (non-life-threatening) and can be effectively managed with targeted therapies like KIT inhibitors.

Receiving a diagnosis of systemic mastocytosis (SM) can feel overwhelming. Because it is a rare disease, you may find that many doctors have never treated it before [1]. It is completely normal to feel anxious, frustrated, or uncertain as you begin this journey [2].

While the name sounds complex, the medical community’s understanding of SM has advanced rapidly in recent years. Today, we know the exact genetic “switch” that drives the disease, and we have developed targeted therapies specifically designed to turn it off [3][4].

Understanding Systemic Mastocytosis

Systemic Mastocytosis (SM) is a rare blood disorder where the body produces too many mast cells [5]. Mast cells are a normal part of your immune system; they are responsible for “guarding” the body and releasing chemicals like histamine when they sense a threat. In SM, these cells are not only too numerous, but they also accumulate in internal organs like the bone marrow, liver, and digestive tract [3][6].

Because these abnormal mast cells are “hyper-reactive,” they can release chemicals unexpectedly, leading to a wide range of symptoms—from skin flushing and abdominal pain to “brain fog” and fatigue [7][8].

Three Stabilizing Facts

If you are feeling unmoored by your diagnosis, consider these three foundational facts that define the modern outlook for SM:

  1. Most cases are not life-threatening: The vast majority of patients have Indolent Systemic Mastocytosis (ISM) [9]. In this form, the disease typically does not progress to more aggressive stages, and patients generally have a near-normal life expectancy [10][11].
  2. The “Driver” is known: Scientists have identified a specific mutation called KIT D816V as the primary driver of the disease in approximately 95% of patients [12][3]. Knowing the exact cause has allowed doctors to move away from guesswork and toward precision medicine [4].
  3. Powerful targeted therapies exist: In the past, treatment focused only on managing symptoms. Today, newer drugs called KIT inhibitors (such as avapritinib or midostaurin) can directly target the abnormal cells to reduce the overall disease burden [13][14].

The Disease Course

The “typical” experience of SM varies significantly depending on the subtype. Current international guidelines categorize the disease into two main groups:

Category Description Primary Goal of Care
Non-Advanced SM Includes Indolent (ISM) and Smoldering (SSM) types. This is the most common form [9]. Controlling symptoms and preventing allergic reactions [8].
Advanced SM Includes aggressive forms and mast cell leukemia. These are much rarer [11]. Reducing the number of mast cells and protecting organ function [15].

Navigating the Emotional Impact

A rare disease diagnosis often brings a “diagnostic odyssey”—a long period of searching for answers that can leave you feeling exhausted [1]. Once diagnosed, the unpredictability of symptoms can cause significant psychological distress [7].

It is important to recognize that your emotional health is just as vital as your physical health. Many patients find that working with a multidisciplinary team—which may include hematologists, allergists, and mental health professionals—is the most effective way to regain a sense of control over their lives [16][8].

Common questions in this guide

What is systemic mastocytosis?
Systemic mastocytosis is a rare blood disorder caused by the overproduction of mast cells. These cells build up in internal organs like the bone marrow and liver, where they can unexpectedly release chemicals that cause various symptoms.
Is systemic mastocytosis life-threatening?
For the vast majority of patients, the disease is an indolent (slow-growing) form that is not life-threatening. People with indolent systemic mastocytosis generally do not progress to more aggressive stages and have a near-normal life expectancy.
What causes systemic mastocytosis?
In approximately 95% of patients, the disease is driven by a specific genetic mutation called KIT D816V. This mutation acts like a faulty switch that tells the body to continuously produce abnormal mast cells.
How is systemic mastocytosis treated?
While past treatments focused only on managing symptoms, modern medicine uses targeted therapies called KIT inhibitors, such as avapritinib or midostaurin. These medications directly target the abnormal mast cells to reduce the overall disease burden.
What are the different types of systemic mastocytosis?
The disease is categorized into two main groups: non-advanced and advanced. Non-advanced forms, which include indolent and smoldering systemic mastocytosis, are by far the most common. Advanced forms are much rarer and require more aggressive care.

Questions to Ask Your Doctor

Curated prompts to bring to your next appointment.

  1. 1.What specific subtype of systemic mastocytosis do I have, and how does that affect my long-term outlook?
  2. 2.Have I been tested for the KIT D816V mutation using a highly sensitive method like ddPCR?
  3. 3.Are you or any members of my care team specialists in mast cell disorders, or should I seek a second opinion from a mastocytosis center?
  4. 4.Which of my current symptoms are caused by 'mediator release,' and which might be caused by 'mast cell burden'?
  5. 5.What are my current 'B-findings' or 'C-findings,' and what do they mean for my treatment plan?

Questions For You

Tap a prompt to share your answer — we'll use it plus this page's context to start a tailored conversation.

References

References (16)
  1. 1

    Bone marrow tryptase as a possible diagnostic criterion for adult systemic mastocytosis.

    Bulai Livideanu C, Apoil PA, Lepage B, et al.

    Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology 2016; (46(1)):133-41 doi:10.1111/cea.12627.

    PMID: 26767494
  2. 2

    A rare manifestation of indolent systemic mastocytosis and its management during the coronavirus disease 2019 pandemic; educational lessons from Syria.

    Slaibi A, Alshehabi Z, Soltany A, et al.

    Annals of medicine and surgery (2012) 2021; (62()):293-297 doi:10.1016/j.amsu.2021.01.062.

    PMID: 33520224
  3. 3

    Patient-reported outcomes among patients with systemic mastocytosis in routine clinical practice: Results of the TouchStone SM Patient Survey.

    Mesa RA, Sullivan EM, Dubinski D, et al.

    Cancer 2022; (128(20)):3691-3699 doi:10.1002/cncr.34420.

    PMID: 35996873
  4. 4

    New treatments for systemic mastocytosis in 2025.

    Costanzo G, Marzio V, Cavaglià E, et al.

    Current opinion in allergy and clinical immunology 2025; (25(4)):277-292 doi:10.1097/ACI.0000000000001079.

    PMID: 40471046
  5. 5

    Comparison between indolent systemic mastocytosis and clonal mast cell disease not meeting WHO diagnostic criteria: A nationwide multicenter retrospective analysis.

    Sciumè M, Serpenti F, Zanotti R, et al.

    Hematological oncology 2024; (42(3)):e3277 doi:10.1002/hon.3277.

    PMID: 38682493
  6. 6

    Systemic mastocytosis in adults: 2021 Update on diagnosis, risk stratification and management.

    Pardanani A

    American journal of hematology 2021; (96(4)):508-525 doi:10.1002/ajh.26118.

    PMID: 33524167
  7. 7

    Patient-Reported Outcomes and Provider Perceptions of Systemic Mastocytosis: Results From the PRISM Study.

    Triggiani M, Hobart J, Alvarez-Twose I, et al.

    Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology 2025; (55(9)):784-794 doi:10.1111/cea.70101.

    PMID: 40579689
  8. 8

    Management of indolent mastocytosis and mast cell activation syndrome: A clinical yardstick.

    Akin C, Butterfield JH, Castells M, Lyons JJ

    Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology 2025; (135(4)):466-477 doi:10.1016/j.anai.2025.06.032.

    PMID: 40592381
  9. 9

    Real-world characteristics of systemic mastocytosis in Romania: insights from a reference-center-based descriptive study.

    Soare D, Soare D, Petruțescu B, et al.

    Journal of medicine and life 2025; (18(7)):640-647 doi:10.25122/jml-2025-0103.

    PMID: 40893810
  10. 10

    Indolent systemic mastocytosis and aleukemic mast cell leukemia: Subtle diagnostic differences with distinct management approaches.

    Paiva ML, Yumeen S, Saliba E, DiMarco C

    JAAD case reports 2023; (36()):63-66 doi:10.1016/j.jdcr.2023.04.009.

    PMID: 37250010
  11. 11

    Management of Advanced Systemic Mastocytosis and Associated Myeloid Neoplasms.

    Tashi T, Deininger MW

    Immunology and allergy clinics of North America 2023; (43(4)):723-741 doi:10.1016/j.iac.2023.04.009.

    PMID: 37758409
  12. 12

    Systemic Mastocytosis and Other Entities Involving Mast Cells: A Practical Review and Update.

    El Hussein S, Chifotides HT, Khoury JD, et al.

    Cancers 2022; (14(14)) doi:10.3390/cancers14143474.

    PMID: 35884535
  13. 13

    Avapritinib versus Placebo in Indolent Systemic Mastocytosis.

    Gotlib J, Castells M, Elberink HO, et al.

    NEJM evidence 2023; (2(6)):EVIDoa2200339 doi:10.1056/EVIDoa2200339.

    PMID: 38320129
  14. 14

    Midostaurin therapy for advanced systemic mastocytosis: Mayo Clinic experience in 33 consecutive cases.

    Singh A, Al-Kali A, Begna KH, et al.

    American journal of hematology 2022; (97(5)):630-637 doi:10.1002/ajh.26498.

    PMID: 35156231
  15. 15

    Safety and efficacy of avapritinib in advanced systemic mastocytosis: the phase 1 EXPLORER trial.

    DeAngelo DJ, Radia DH, George TI, et al.

    Nature medicine 2021; (27(12)):2183-2191 doi:10.1038/s41591-021-01538-9.

    PMID: 34873347
  16. 16

    Tyrosine Kinase Inhibition in Mastocytosis: KIT and Beyond KIT.

    Bibi S, Arock M

    Immunology and allergy clinics of North America 2018; (38(3)):527-543 doi:10.1016/j.iac.2018.04.007.

    PMID: 30007468

This page provides a general overview of systemic mastocytosis for educational purposes only. Always consult your hematologist or mast cell specialist for personalized medical advice regarding your specific diagnosis and treatment plan.

Get notified when new evidence is published on Systemic mastocytosis.

We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.